Syndax said its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint of slowing lung function decline, so it will halt further IPF development for the drug while other trials continue. Safety in IPF was comparable to placebo, and ongoing studies and the approved chronic GVHD use of Niktimvo are unaffected. The article views the setback as a narrowing of axatilimab's opportunity rather than a franchise-level issue, with Revuforj and Niktimvo still the core commercial pillars. However, Syndax remains loss-making and spends roughly US$400 million a year on R&D and SG&A, so revenue growth is the key factor to watch.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Get briefings and signals on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the morning, midday and evening briefing of each market and important news as it happens.